AMP Workshop: Guideline-Driven PGX Testing: A new, targeted testing approach covering all AMP Tier 1 and Tier 2 pharmacogenomic recommendations

Guideline-Driven PGx Testing: A new, targeted testing approach covering all AMP Tier 1 and Tier 2 pharmacogenomic recommendations.

Wednesday, November 12, 2025 | 12:00 – 12:50 PM EST
Room #159, Level 1

Dr. Jai Patel, Associate VP of Translational Research and Director of Cancer Pharmacology & Pharmacogenomics at Atrium Health Levine Cancer, and Dr. Vicky Pratt, past president of AMP, have been leading voices in pharmacogenomics—driving the adoption of standardized, guideline-driven testing across research laboratories.

Join them as they share insights on the development and implementation of the new VeriDose® Core v2.0 Panel, designed to align with all AMP Tier 1 and Tier 2 allele recommendations for genes including CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, TPMT, and NUDT15. Learn how this targeted approach supports standardized, scalable pharmacogenomics research on the MassARRAY® System.

Learning Objectives

Review AMP Tier 1 and Tier 2 pharmacogenomic recommendations.
See how the VeriDose® Core v2.0 PGx Panel standardizes allele coverage.
Explore implementation of PGx research workflows on the MassARRAY® System.
Discuss emerging trends in guideline-driven pharmacogenomics research.

An AMP Annual Meeting badge or Corporate Workshop Day badge is required to attend this workshop.

PRESENTED BY:

Jai Patel, PharmD

Associate Vice President Translational Research; Director of Cancer Pharmacology & Pharmacogenomics; Associate Professor, Cancer Biology

Dr. Patel is the Associate Vice President of Translational Research and Director of Cancer Pharmacology & Pharmacogenomics at Atrium Health Levine Cancer and Associate Director for Shared Resources Management at Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He is also Associate Professor in the Department of Cancer Biology at the Wake Forest University School of Medicine.

Dr. Patel received his Doctorate in Pharmacy from the University of North Carolina Eshelman School of Pharmacy and completed an oncology pharmacogenomics postdoctoral fellowship at the UNC Center for Pharmacogenomics and Individualized Therapy. Dr. Patel leads translational and clinical pharmacology research at the cancer center, with an emphasis on pharmacogenomics research and implementation, and oversees pharmacogenomics integration across the health enterprise. Dr. Patel has published over 170 articles, editorials, book chapters and abstracts on the topics of pharmacogenomics, pharmacology, and pharmaceutical sciences.

Victoria M. Pratt, PhD, FACMG

Director of Scientific Affairs for Pharmacogenetics, Agena Bioscience

Dr. Pratt is the Past President of the Association for Molecular Pathology. Dr. Pratt continues to serve on the Centers for Disease Control and Prevention (CDC) GeT-RM Genetic Testing Reference Materials Program, the National Academy of Medicine’s Roundtable on Genomics and Precision Health, and the American Medical Association’s (AMA) Molecular Pathology Current Procedural Terminology (CPT) Advisory Committee.

Dr. Pratt graduated with a Ph.D. in Medical and Molecular Genetics from Indiana University School of Medicine. Her fellowship training was in Medical and Clinical Molecular Genetics at Henry Ford Hospital, Detroit MI.

Pharmacogenetics Workshop

Learning Objectives

Save your seat & get the replay

About Agena Bioscience

Connect